Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.36 |
| ▸ | BTK | Q06187 | 3/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 4/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23210795 | 1.00 | JAK2 (0.36) | JAK2BTKESR2LPLLIPG | |
| SCHEMBL30821196 | 0.86 | LPL (0.39) | ESR2LPLLIPGALDH1A1HPGD | |
| SCHEMBL534206 | 0.86 | LPL (0.39) | ESR2LPLLIPGALDH1A1HPGD | |
| SCHEMBL17660374 | 0.81 | JAK2 (0.41) | JAK2BTKLPLLIPG | |
| SCHEMBL29288003 | 0.80 | JAK2 (0.38) | JAK2BTKLPLLIPG | |
| SCHEMBL20540433 | 0.80 | JAK2 (0.39) | JAK2BTKLPLLIPG | |
| SCHEMBL15000450 | 0.80 | PDCD1 (0.42) | JAK2BTKLPLLIPG | |
| SCHEMBL29712932 | 0.80 | PDCD1 (0.42) | JAK2BTKLPLLIPG | |
| SCHEMBL11927624 | 0.78 | LPL (0.44) | JAK2BTKLPLLIPG | |
| SCHEMBL21805011 | 0.77 | MAP4K1 (0.46) | JAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2025-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | JAK2 89/4885BTK 193/4885ESR2 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.